COVID-19 associated mucormycosis (CAM) in Kashan, Iran: clinical presentations, risk factors, management, and outcomes

References

• Erami M, Raiesi O, Momen-Heravi M, et al. Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia. Microb Pathog. 2022;166:105520. doi: 10.1016/j.micpath.2022.105520.
   PubMed Web of Science ®Google Scholar
• Dilek A, Ozaras R, Ozkaya S, et al. COVID-19-associated mucormycosis: case report and systematic review. Travel Med Infect Dis. 2021;44:102148. doi: 10.1016/j.tmaid.2021.102148.
   PubMed Web of Science ®Google Scholar
• Erami M, Hashemi SJ, Raiesi O, et al. COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia. Infection. 2023;51(1):223–230. doi: 10.1007/s15010-022-01907-7.
   PubMed Web of Science ®Google Scholar
• Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: a systematic review and meta‐analysis. Mycoses. 2021;64(9):993–1001. doi: 10.1111/myc.13292.
   PubMed Web of Science ®Google Scholar
• Raiesi O, Hashemi SJ, Getso MI, et al. First report of chronic invasive fungal rhinosinusitis in a patient with ovarian cancer caused by Didymella pedeiae and successful treatment with voriconazole: a case report. Curr Med Mycol. 2021;7(1):55–58. doi: 10.18502/cmm.7.1.6244.
   PubMedGoogle Scholar
• Raiesi O, Shabandoust H, Getso M, et al. Candida auris: a new emerging fungal monster. Arch Clin Infect Dis. 2019;14(2):e70741. doi: 10.5812/archcid.70741.
   PubMed Web of Science ®Google Scholar
• Das AK, Mani SK, Singh SK. Surgical management of post-COVID invasive rhino-orbito-cerebral mucormycosis and its outcomes: role of neurosurgeons in a tertiary care center. Surg Neurol Int. 2022;13:335. doi: 10.25259/SNI_374_2022.
   PubMedGoogle Scholar
• Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. doi: 10.1016/j.dsx.2021.05.019.
   PubMed Web of Science ®Google Scholar
• Sharma A, Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol. 2022;67(3):363–387. doi: 10.1007/s12223-021-00934-5.
   PubMed Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34. doi: 10.1016/j.cmi.2018.07.011.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–509. doi: 10.1086/590004.
   PubMed Web of Science ®Google Scholar
• Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42(264):e5-264–e8. doi: 10.1016/j.ajem.2020.09.032.
   Google Scholar
• Mahalaxmi I, Jayaramayya K, Venkatesan D, et al. Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res. 2021;201:111643. doi: 10.1016/j.envres.2021.111643.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Edwards J, Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–569. doi: 10.1128/CMR.18.3.556-569.2005.
   PubMed Web of Science ®Google Scholar
• Dantas KC, Mauad T, de André CDS, et al. A single-centre, retrospective study of the incidence of invasive fungal infections during 85 years of autopsy service in Brazil. Sci Rep. 2021;11(1):3943. doi: 10.1038/s41598-021-83587-1.
   PubMed Web of Science ®Google Scholar
• Boroujeni ZB, Shamsaei S, Yarahmadi M, et al. Distribution of invasive fungal infections: molecular epidemiology, etiology, clinical conditions, diagnosis and risk factors: a 3-year experience with 490 patients under intensive care. Microb Pathog. 2021;152:104616. doi: 10.1016/j.micpath.2020.104616.
   PubMed Web of Science ®Google Scholar
• Raiesi O, Hashemi SJ, Ardehali MM, et al. Molecular identification and clinical features of fungal rhinosinusitis: a 3-year experience with 108 patients. Microb Pathog. 2021;158:105018. doi: 10.1016/j.micpath.2021.105018.
   PubMed Web of Science ®Google Scholar
• Shamsaei S, Falahati M, Farahyar S, et al. Acute invasive fungal rhinosinusitis: molecular identification and update in management of frozen section biopsy. Microb Pathog. 2021;159:105125. doi: 10.1016/j.micpath.2021.105125.
   PubMed Web of Science ®Google Scholar
• Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European confederation of medical mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–1867. doi: 10.1111/j.1469-0691.2010.03456.x.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Chatterjee S, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85(1009):573–581. doi: 10.1136/pgmj.2008.076463.
   PubMed Web of Science ®Google Scholar
• Dolatabadi S, Ahmadi B, Rezaei-Matehkolaei A, et al. Mucormycosis in Iran: a six-year retrospective experience. J Mycol Med. 2018;28(2):269–273. doi: 10.1016/j.mycmed.2018.02.014.
   PubMed Web of Science ®Google Scholar
• Stemler J, Hamed K, Salmanton‐García J, et al. Mucormycosis in the Middle East and North Africa: analysis of the FungiScope® registry and cases from the literature. Mycoses. 2020;63(10):1060–1068. doi: 10.1111/myc.13123.
   PubMed Web of Science ®Google Scholar
• Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, et al. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29–43. doi: 10.1093/mmy/myx017.
   PubMed Web of Science ®Google Scholar
• Dubey S, Mukherjee D, Sarkar P, et al. COVID-19 associated rhino-orbital-cerebral mucormycosis: an observational study from Eastern India, with special emphasis on neurological spectrum. Diabetes Metab Syndr. 2021;15(5):102267. doi: 10.1016/j.dsx.2021.102267.
   PubMed Web of Science ®Google Scholar
• Suryanarayanan T, Shaanker U. COVID-19 and black fungus: what is mucormycosis. Health Sci. 2021.
   Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. doi: 10.1086/432579.
   PubMed Web of Science ®Google Scholar
• Riad A, Shabaan AA, Issa J, et al. COVID-19-associated mucormycosis (CAM): case-series and global analysis of mortality risk factors. JoF. 2021;7(10):837. doi: 10.3390/jof7100837.
   Google Scholar
• Abdorahimi M, Pakdel F, Salehi M, et al. COVID-19 associated rhino-orbital-cerebral mucormycosis: clinical features, antifungal susceptibility, management and outcome in a tertiary hospital in Iran. Mycopathologia. 2023. doi: 10.1007/s11046-023-00785-3.
   PubMed Web of Science ®Google Scholar
• Taneja J, Chatterjee K, Sasidharan J, et al. Post-COVID-19 rhino-orbito-cerebral mucormycosis—a clinico-mycological study from North India. Med Mycol. 2023;61(7):myad067. doi: 10.1093/mmy/myad067.
   PubMed Web of Science ®Google Scholar
• Alloush TK, Mansour O, Alloush AT, et al. Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital. Neurol Sci. 2022;43(2):799–809. doi: 10.1007/s10072-021-05740-y.
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543–e552. doi: 10.1016/S2666-5247(21)00237-8.
   PubMedGoogle Scholar
• Ravindra K, Ahlawat A. Five probable factors responsible for the COVID-associated mucormycosis outbreak in India. Int J Infect Dis. 2021;112:278–280. doi: 10.1016/j.ijid.2021.09.057.
   PubMed Web of Science ®Google Scholar
• Bala K, Chander J, Handa U, et al. A prospective study of mucormycosis in North India: experience from a tertiary care hospital. Med Mycol. 2015;53(3):248–257. doi: 10.1093/mmy/myu086.
   PubMed Web of Science ®Google Scholar
• Dallalzadeh LO, Ozzello DJ, Liu CY, et al. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2022;41(5):616–619. doi: 10.1080/01676830.2021.1903044.
   PubMedGoogle Scholar
• Mishra Y, Prashar M, Sharma D, Kumar VP, Tilak T. Diabetes, COVID 19 and mucormycosis: clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr. 2021;15(4):102196. doi: 10.1016/j.dsx.2021.102196.
   PubMed Web of Science ®Google Scholar
• Gupta R, Kesavadev J, Krishnan G, et al. COVID-19 associated mucormycosis: a descriptive multisite study from India. Diabetes Metab Syndr. 2021;15(6):102322. doi: 10.1016/j.dsx.2021.102322.
   PubMed Web of Science ®Google Scholar
• Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349–2359. doi: 10.3201/eid2709.210934.
   PubMed Web of Science ®Google Scholar
• Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India–collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol. 2021;69(7):1670–1692. doi: 10.4103/ijo.IJO_1565_21.
   PubMed Web of Science ®Google Scholar
• Saadi MHG, Hosseini SA, Khodamoradi Z, et al. Comparison of mucormycosis infection between patients with and without a history of COVID-19 infection: a retrospective cohort study. Trans R Soc Trop Med Hyg. 2023;117(3):174–178. doi: 10.1093/trstmh/trac078.
   PubMed Web of Science ®Google Scholar
• Ramaswami A, Sahu AK, Kumar A, et al. COVID-19-associated mucormycosis presenting to the emergency department—an observational study of 70 patients. QJM. 2021;114(7):464–470. doi: 10.1093/qjmed/hcab190.
   PubMed Web of Science ®Google Scholar
• Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am. 2000;33(2):349–365. doi: 10.1016/s0030-6665(00)80010-9.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Sarma P, Sharma DJ, et al. Rhino-orbital-cerebral-mucormycosis in COVID-19: a systematic review. Indian Journal of Pharmacology. 2021;53(4):317.
   PubMed Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. JoF. 2019;5(1):26. doi: 10.3390/jof5010026.
   Google Scholar
• Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395–402. doi: 10.1093/mmy/myy060.
   PubMed Web of Science ®Google Scholar
• Singh Y, Ganesh V, Kumar S, et al. Coronavirus disease-associated mucormycosis from a tertiary care hospital in India: a case series. Cureus. 2021;13(7):e16152. doi: 10.7759/cureus.16152.
   PubMed Web of Science ®Google Scholar
• Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicentre study from Iran. Mycoses. 2021;64(10):1238–1252. doi: 10.1111/myc.13334.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Gokhale T, Choudhury SS, et al. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021;69(4):1002–1004. doi: 10.4103/ijo.IJO_3763_20.
   PubMed Web of Science ®Google Scholar